News

October 6, 2021:

Fortress Biotech Announces Closing of Acquisition of Caelum Biosciences by AstraZeneca

September 29, 2021:

Fortress Biotech Announces Receipt of Notice of Option Exercise from AstraZeneca to Fully Acquire Caelum Biosciences, a Company Founded by Fortress Biotech

June 11, 2021:

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

May 12, 2021:

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

March 1, 2021:

Caelum Biosciences Announces Collaborations with the Amyloidosis Advocacy Community and Support of Amyloidosis Awareness Month

November 4, 2020:

Caelum and Alexion Announce Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

September 14, 2020:

Alexion and Caelum Biosciences Announce Start of Phase 3 Studies of CAEL-101 in AL Amyloidosis

December 2, 2019:

Caelum Biosciences Granted Orphan Medicinal Product Designation from the European Commission for CAEL-101 for the Treatment of AL Amyloidosis

January 31, 2019:

Alexion and Caelum Biosciences Announce Collaboration to Develop Targeted Therapy for Light Chain (AL) Amyloidosis

December 4, 2018:

Caelum Biosciences Announces Two Oral Presentations of Additional Data from Phase 1b Study of Anti-Amyloid mAb CAEL-101 and Preclinical Imaging Study at 60th American Society of Hematology Annual Meeting

November 2, 2018:

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentations at 60th American Society of Hematology Annual Meeting

June 25, 2018:

Caelum Biosciences Announces Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis

June 18, 2018:

Caelum Biosciences Announces Presentation of Complete Cardiac Data Analysis from Phase 1b Trial of CAEL-101 in AL Amyloidosis at American Society of Echocardiography 29th Annual Scientific Sessions

April 20, 2018:

Caelum Biosciences Submits Draft Registration Statement on Form S-1 to the Securities and Exchange Commission

March 27, 2018

Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis

March 21, 2018:

Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis

December 11, 2017:

Caelum Biosciences Announces Positive Phase 1a/1b Data Demonstrating CAEL-101 (mAb 11-1F4) Improves Organ Function in AL Amyloidosis

November 1, 2017:

Caelum Biosciences Announces Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 59th American Society of Hematology Annual Meeting

July 17, 2017:

Fortress Biotech Announces Filing of Provisional Application for Caelum Biosciences’ CAEL-101

June 1, 2017:

Fortress Biotech Subsidiary Caelum Biosciences Enters Biopharmaceutical Manufacturing Agreement With Patheon

May 4, 2017:

Fortress Biotech Announces Final Patient Dosed in Phase 1B Trial of CAEL-101 for the Treatment of AL Amyloidosis

April, 5, 2017:

Fortress Biotech Announces Orphan Drug Designations for CAEL-101 in Amyloidosis

January 4, 2017:

Fortress Biotech forms a new subsidiary, Caelum Biosciences, Inc., to develop a novel treatment for AL Amyloidosis